Inhibikase Therapeutics Valuation
Is IKT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IKT?
Other financial metrics that can be useful for relative valuation.
|What is IKT's n/a Ratio?|
Price to Book Ratio vs Peers
How does IKT's PB Ratio compare to its peers?
|IKT PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
BPTH Bio-Path Holdings
IMMX Immix Biopharma
IKT Inhibikase Therapeutics
Price-To-Book vs Peers: IKT is good value based on its Price-To-Book Ratio (0.9x) compared to the peer average (1x).
Price to Earnings Ratio vs Industry
How does IKT's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: IKT is good value based on its Price-To-Book Ratio (0.9x) compared to the US Biotechs industry average (1.7x)
Price to Book Ratio vs Fair Ratio
What is IKT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.9x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate IKT's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of IKT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IKT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IKT's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.